logo
Plus   Neg
Share
Email

Kiniksa Pharma: KPL-716 Phase 1a/1b Achieves Its Study Goals

Kiniksa Pharmaceuticals, Ltd. (KNSA) presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta. In the First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. KPL-716 also demonstrated a reduction in pruritus. The company said the results support its plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis.

"Data from the single-dose cohorts of the placebo-controlled Phase 1a/1b of KPL-716 achieved the goals established for the study. The results provided us with data on the safety and tolerability of KPL-716 as well as the anti-pruritic effect of the drug," said Sanj Patel, CEO and Chairman of the Board of Kiniksa.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Harley-Davidson, in collaboration with Qianjiang Motorcycle co., plan to launch smaller engine capacity bikes of 338 CC in China by 2020. This is part of the company's strategic move to expand its bike production to Asian countries. The Chief Executive Officers of VMware, Inc. (VMW(, Microsoft Corp. (MSFT) and its unit LinkedIn Corp. are among the most popular with their respective employees, according to job and recruiting site Glassdoor's annual Employees' Choice Awards for Top CEOs in 2019. The awards feature six distinct company categories across North America and parts of Europe. Amazon.com Inc. has named Elizabeth Gilbert's novel City of Girls as the best book of 2019 so far. The annual list, compiled by Amazon editors and released by the online retailer, features the Top 20 books of the year that were published between January and June 2019. It also features the best books across various categories, including literary fiction, mystery and thriller, and biography.
Follow RTT